EP2224924A4 - Compositions et procédés destinés au traitement de la fibrose kystique - Google Patents

Compositions et procédés destinés au traitement de la fibrose kystique

Info

Publication number
EP2224924A4
EP2224924A4 EP08841991A EP08841991A EP2224924A4 EP 2224924 A4 EP2224924 A4 EP 2224924A4 EP 08841991 A EP08841991 A EP 08841991A EP 08841991 A EP08841991 A EP 08841991A EP 2224924 A4 EP2224924 A4 EP 2224924A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treatment
methods
cystic fibrosis
cystic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08841991A
Other languages
German (de)
English (en)
Other versions
EP2224924A1 (fr
Inventor
Richard L Watson
Anthony B Wood
Gregory J Archambeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microdiffusion Inc
Original Assignee
Microdiffusion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2007/082580 external-priority patent/WO2008052145A2/fr
Priority claimed from PCT/US2007/082578 external-priority patent/WO2008052143A2/fr
Priority claimed from PCT/US2007/082581 external-priority patent/WO2008115290A2/fr
Application filed by Microdiffusion Inc filed Critical Microdiffusion Inc
Priority claimed from PCT/US2008/081113 external-priority patent/WO2009055671A1/fr
Publication of EP2224924A1 publication Critical patent/EP2224924A1/fr
Publication of EP2224924A4 publication Critical patent/EP2224924A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
EP08841991A 2007-10-25 2008-10-24 Compositions et procédés destinés au traitement de la fibrose kystique Withdrawn EP2224924A4 (fr)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US98271907P 2007-10-25 2007-10-25
US98272007P 2007-10-25 2007-10-25
PCT/US2007/082580 WO2008052145A2 (fr) 2006-10-25 2007-10-25 Procédés de traitement thérapeutique des yeux et d'autres tissus humains à l'aide d'une solution enrichie en oxygène
PCT/US2007/082578 WO2008052143A2 (fr) 2006-10-25 2007-10-25 Dispositif de mélange et ses fluides de sortie
PCT/US2007/082581 WO2008115290A2 (fr) 2006-10-25 2007-10-25 Méthodes de soins et de traitement de plaies
US4834708P 2008-04-28 2008-04-28
US4834008P 2008-04-28 2008-04-28
US4840408P 2008-04-28 2008-04-28
US4833208P 2008-04-28 2008-04-28
PCT/US2008/081113 WO2009055671A1 (fr) 2007-10-25 2008-10-24 Compositions et procédés destinés au traitement de la fibrose kystique

Publications (2)

Publication Number Publication Date
EP2224924A1 EP2224924A1 (fr) 2010-09-08
EP2224924A4 true EP2224924A4 (fr) 2011-01-12

Family

ID=42261767

Family Applications (3)

Application Number Title Priority Date Filing Date
EP08842968A Withdrawn EP2215260A4 (fr) 2007-10-25 2008-10-23 Compositions et procédés pour moduler la transduction de signal intracellulaire véhiculé par membrane cellulaire
EP08841991A Withdrawn EP2224924A4 (fr) 2007-10-25 2008-10-24 Compositions et procédés destinés au traitement de la fibrose kystique
EP08841701.9A Active EP2214707B1 (fr) 2007-10-25 2008-10-24 Compositions et procédés pour traiter une inflammation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP08842968A Withdrawn EP2215260A4 (fr) 2007-10-25 2008-10-23 Compositions et procédés pour moduler la transduction de signal intracellulaire véhiculé par membrane cellulaire

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP08841701.9A Active EP2214707B1 (fr) 2007-10-25 2008-10-24 Compositions et procédés pour traiter une inflammation

Country Status (8)

Country Link
EP (3) EP2215260A4 (fr)
JP (6) JP5613565B2 (fr)
CN (5) CN101910412B (fr)
AU (3) AU2008316794B2 (fr)
CA (3) CA2703672A1 (fr)
IL (3) IL205318A (fr)
MX (3) MX2010004563A (fr)
WO (1) WO2009055614A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
US8597689B2 (en) 2006-10-25 2013-12-03 Revalesio Corporation Methods of wound care and treatment
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
AU2007308838B2 (en) 2006-10-25 2014-03-13 Revalesio Corporation Mixing device and output fluids of same
CA2703648A1 (fr) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions bacteriostatiques ou bacteriocides et procedes
EP2215260A4 (fr) * 2007-10-25 2011-04-20 Revalesio Corp Compositions et procédés pour moduler la transduction de signal intracellulaire véhiculé par membrane cellulaire
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
MX337862B (es) * 2008-04-28 2016-03-16 Revalesio Corp Composiciones y métodos para el tratamiento de la esclerosis multiple.
EP2285347A4 (fr) 2008-05-01 2011-09-21 Revalesio Corp Compositions et méthodes de traitement de troubles digestifs
EP2364154A4 (fr) * 2008-10-22 2013-07-10 Revalesio Corp Compositions et procédés pour traiter des affections véhiculées par la métalloprotéinase matricielle 9 (mmp9)
MX2011011333A (es) * 2009-04-27 2011-11-18 Revalesio Corp Composiciones y metodos para tratar la resistencia a la insulina y la diabetes mellituscampo de la invencion.
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
KR20130114581A (ko) * 2010-05-07 2013-10-18 레발레시오 코퍼레이션 생리적 수행능력 및 회복 시간의 향상을 위한 조성물 및 방법
KR101801864B1 (ko) 2010-06-16 2017-11-27 인플래머토리 리스폰스 리서치, 아이엔씨. 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
JP2013533320A (ja) 2010-08-12 2013-08-22 レバレジオ コーポレイション タウオパチーを治療するための組成物および方法
WO2012021860A1 (fr) * 2010-08-13 2012-02-16 Revalesio Corporation Compositions et méthodes utilisables en vue du traitement des maladies cardiovasculaires
JP2014511879A (ja) * 2011-04-13 2014-05-19 レバレジオ コーポレイション 炎症性神経変性疾患に関与するエフェクターｔ細胞を抑制および／または調節する組成物および方法
JP6368459B2 (ja) * 2012-06-14 2018-08-01 松本　高明 点眼液の製造方法
EP2968309A4 (fr) 2013-03-13 2016-08-31 Inflammatory Response Res Inc Utilisation de lévocétirizine et de montelukast dans le traitement de la vascularite
ES2660494T3 (es) 2013-03-13 2018-03-22 14779507 Uso de levocetirizina y montelukast en el tratamiento de una lesión traumática
WO2014164299A1 (fr) 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Utilisation de levocetirizine et de montelukast dans le traitement des maladies auto-immunes
EP3193875B1 (fr) 2014-09-15 2022-02-16 Inflammatory Response Research, Inc. Lévocétirizine et montélukast dans le traitement de troubles médiés par une inflammation
CN106943593A (zh) * 2017-03-24 2017-07-14 浙江中医药大学 抗tslp抗体在制备防治慢性瘙痒药物中的应用
CA3064050A1 (fr) * 2017-05-23 2018-11-29 Biovite Australia Pty Ltd. Extraits d'arthrospira et leurs utilisations
EP4153178A4 (fr) 2020-05-19 2024-06-05 Irr, Inc. Lévocétirizine et montélukast utilisés dans le traitement du sepsis et de ses symptômes
CN112305153B (zh) * 2020-10-16 2022-09-23 中石化石油工程技术服务有限公司 一种膨润土含量的自动分析检测仪及其检测方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040129112A1 (en) * 2000-07-27 2004-07-08 Gillis Scott H. Metal-containing materials
WO2005113026A2 (fr) * 2004-04-22 2005-12-01 Medical Discoveries, Inc. Procede de traitement des troubles respiratoires et de l'inflammation des voies respiratoires
WO2008052143A2 (fr) * 2006-10-25 2008-05-02 Revalesio Corporation Dispositif de mélange et ses fluides de sortie

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518483D0 (en) * 1995-09-09 1995-11-08 Thompson Royce Ltd Lighting control systems
US6386751B1 (en) * 1997-10-24 2002-05-14 Diffusion Dynamics, Inc. Diffuser/emulsifier
US7654728B2 (en) * 1997-10-24 2010-02-02 Revalesio Corporation System and method for therapeutic application of dissolved oxygen
ES2289817T3 (es) * 1998-07-28 2008-02-01 The Regents Of The University Of California Acidos nucleicos que codifican un receptor acoplado a proteinas e implicado en la transduccion sensorial.
US20060198901A9 (en) * 1999-10-26 2006-09-07 Holloway William D Jr Drugs, bio-affecting and body treating compositions
EP1237578A4 (fr) * 1999-10-26 2004-10-27 Bio Hydration Res Lab Inc Liquides micro-agreges et leurs procedes de fabrication et d'utilisation
EP1252305A2 (fr) * 1999-12-08 2002-10-30 Genset Adnc humains pleine longueur codant pour des proteines potentiellement secretees
AU2001292867A1 (en) * 2000-09-20 2002-04-02 The Cleveland Clinic Foundation Ligands for g protein coupled receptors and methods of using them
US20040235732A1 (en) * 2000-11-03 2004-11-25 Qun-Yong Zhou Method for modulating angiogenesis using prokineticin receptor antagonists
WO2002060458A2 (fr) * 2001-02-01 2002-08-08 Hydron Technologies, Inc. Compositions et procede de superoxygenation tissulaire
GB0118383D0 (en) * 2001-07-27 2001-09-19 Pharmagene Lab Ltd Therapeutic methods
DE10227818A1 (de) * 2002-06-21 2004-01-08 Pakdaman, Abolghassem, Prof. Dr.med. Gasanreicherungsmodule
AU2002321678A1 (en) * 2002-09-09 2004-03-29 Boros Béla Oxygen-enriched water, treated within a magnetic field and heavy water
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
BRPI0416319A (pt) * 2003-11-10 2007-01-09 Merck & Co Inc composto, composição farmacêutica, métodos de tratamento ou prevenção da dor, das sìndromes, e de doença, e, métodos de administrar anestesia local, e para a neuroproteção sob condições isquêmicas
US20050139808A1 (en) * 2003-12-30 2005-06-30 Oculus Innovative Sciences, Inc. Oxidative reductive potential water solution and process for producing same
EP1879568B1 (fr) * 2005-03-28 2009-05-06 Dabur Pharma Limited Preparations pharmaceutiques stables d agents antitumoraux contenant du platine(ii)
DK1901749T3 (en) * 2005-05-18 2016-10-24 Raptor Pharmaceuticals Inc Aerosolized fluoroquinolones AND USES THEREOF
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
CA2667614A1 (fr) * 2006-10-25 2008-09-25 Revalesio Corporation Methodes de soins et de traitement de plaies
US8597689B2 (en) * 2006-10-25 2013-12-03 Revalesio Corporation Methods of wound care and treatment
CA2703648A1 (fr) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions bacteriostatiques ou bacteriocides et procedes
EP2215260A4 (fr) * 2007-10-25 2011-04-20 Revalesio Corp Compositions et procédés pour moduler la transduction de signal intracellulaire véhiculé par membrane cellulaire

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040129112A1 (en) * 2000-07-27 2004-07-08 Gillis Scott H. Metal-containing materials
WO2005113026A2 (fr) * 2004-04-22 2005-12-01 Medical Discoveries, Inc. Procede de traitement des troubles respiratoires et de l'inflammation des voies respiratoires
WO2008052143A2 (fr) * 2006-10-25 2008-05-02 Revalesio Corporation Dispositif de mélange et ses fluides de sortie

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GILL S ET AL: "Nanoparticles: Characteristics, mechanisms of action, and toxicity in pulmonary drug delivery - A review", JOURNAL OF BIOMEDICAL NANOTECHNOLOGY 200706 US LNKD- DOI:10.1166/JBN.2007.015, vol. 3, no. 2, June 2007 (2007-06-01), pages 107 - 119, XP009141494, ISSN: 1550-7033 *
See also references of WO2009055671A1 *

Also Published As

Publication number Publication date
CN103933567A (zh) 2014-07-23
JP2011500844A (ja) 2011-01-06
JP5613565B2 (ja) 2014-10-22
WO2009055614A1 (fr) 2009-04-30
AU2008316623A1 (en) 2009-04-30
CN101910412B (zh) 2013-08-21
CA2703672A1 (fr) 2009-04-30
MX2010004563A (es) 2010-07-28
CN101910412A (zh) 2010-12-08
MX2010004564A (es) 2010-07-28
CN101909648A (zh) 2010-12-08
IL205317A0 (en) 2010-12-30
EP2215260A4 (fr) 2011-04-20
JP2011500837A (ja) 2011-01-06
CN101909623B (zh) 2015-04-01
AU2008316794A1 (en) 2009-04-30
JP5911197B2 (ja) 2016-04-27
IL205319A0 (en) 2010-12-30
CA2703754A1 (fr) 2009-04-30
EP2214707A4 (fr) 2011-04-20
EP2215260A1 (fr) 2010-08-11
CN104771758A (zh) 2015-07-15
IL205319A (en) 2016-06-30
CN101909648B (zh) 2014-04-16
CA2703739A1 (fr) 2009-04-30
EP2214707A1 (fr) 2010-08-11
JP5869763B2 (ja) 2016-02-24
JP2014205693A (ja) 2014-10-30
JP2011500847A (ja) 2011-01-06
AU2008316794B2 (en) 2015-04-23
CN101909623A (zh) 2010-12-08
IL205318A0 (en) 2010-12-30
JP2014193915A (ja) 2014-10-09
EP2224924A1 (fr) 2010-09-08
AU2008316663B2 (en) 2014-12-18
AU2008316623B2 (en) 2015-01-22
JP2014169328A (ja) 2014-09-18
CA2703754C (fr) 2019-04-09
EP2214707B1 (fr) 2017-07-12
MX2010004554A (es) 2010-07-28
AU2008316663A1 (en) 2009-04-30
IL205317A (en) 2016-03-31
IL205318A (en) 2017-01-31

Similar Documents

Publication Publication Date Title
EP2224924A4 (fr) Compositions et procédés destinés au traitement de la fibrose kystique
EP2376410A4 (fr) Compositions et procédés de nettoyage
EP2209371A4 (fr) Compositions et procédés pour le traitement de la rétinopathie diabétique
EP2271301A4 (fr) Procédés et compositions pour la délivrance d agents
EP2340027A4 (fr) Procédés et compositions destinés au traitement du cancer
EP2376656A4 (fr) Procédés de détermination de l'efficacité d'un traitement par glucocorticoïde de l' sophagite à éosinophiles
EP2262474A4 (fr) Procédés et compositions pour la cicatrisation
EP2207669A4 (fr) Compositions bactériostatiques ou bactériocides et procédés
EP2337569A4 (fr) Compositions et procédés de caractérisation et de restauration du microbiote gastro-intestinal, cutané et nasal
EP2120580A4 (fr) Compositions et procédés de traitement de troubles métaboliques
EP2352517A4 (fr) Procédés et compositions pour le traitement de troubles associés au complément
EP2092445A4 (fr) Résultats de recherche imbriqués
EP2056675A4 (fr) Procédés de traitement de mucosites orales
EP2365978A4 (fr) Compositions de lécithine et de plastifiant et procédés
EP2286217A4 (fr) Procédés et compositions de charge de molécule individuelle
EP2207424A4 (fr) Compositions et procédés de traitement du purpura
EP2320937A4 (fr) Compositions et procédés pour le traitement du stress oxydatif oculaire et de la rétinite pigmentaire
EP2271329A4 (fr) Procédés, compositions et kits pour traiter la douleur et le prurit
EP2344447A4 (fr) Conjugués gaba et procédés d'utilisation de ceux-ci
EP2300011A4 (fr) Procédés et composés thérapeutiques
EP2294192A4 (fr) Compositions et procédés de traitement et de vaccination contre le virus de la dengue (vd)
EP2068865A4 (fr) Procédés et compositions pour traitement thérapeutique
EP2349320A4 (fr) Compositions et procédés destinés au traitement de troubles rénaux
EP2419136A4 (fr) Compositions et procédés destinés au traitement du cancer
EP2211856A4 (fr) Compositions et procédés pour traiter des maladies lysosomales

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100521

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20101213

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20140822

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20160927